Fortitude Biomedicines launches with $13M in financing to advance novel antibody-based therapies for treatment of autoimmune diseases and cancer

CAR-T Digest - August 2020

Weekly Digest - January 2026

26 January 2026: Fortitude Biomedicines launches with $13M in financing to advance novel antibody-based therapies for treatment of autoimmune diseases and cancer

Fortitude Biomedicines has officially launched with $13 million in Seed financing, marking the debut of a new biopharmaceutical company focused on advancing antibody-based therapies for autoimmune diseases and cancer. The financing was co-led by K2 Bio Partners, Shanghai Healthcare Angel Capital, and Elikon Venture, with participation from Everjoy Fortune and Taihill Venture
The funding will accelerate Fortitude’s lead immune cell–targeting biologic toward IND-enabling studies, while also supporting the expansion of its broader oncology and autoimmune pipeline through the company’s proprietary GLUE-DAC™ discovery platform
GLUE-DAC™ represents a next-generation antibody–drug conjugate platform, combining the precision of antibody targeting with molecular glue–based targeted protein degradation. Originally developed in Professor Jin Wang’s laboratory at Baylor College of Medicine, the platform aims to overcome resistance, expand the therapeutic window of ADCs, and unlock previously inaccessible targets
With strong investor backing, a differentiated technology platform, and a globally experienced leadership team, Fortitude Biomedicines is positioning itself at the forefront of next-generation biologics and ADC innovation, aiming to redefine precision medicine and deliver transformative therapies to patients worldwide